Real-World Data Study Shows that Biologics are Widely Used and Effective for Severe Asthma

June 24, 2022

A new real-world data (RWD) study published in the Annals of Allergy, Asthma & Immunology shows that biologics are both commonly used and very effective in the treatment of severe asthma. The results, taken from the ongoing CHRONICLE study, found that two-thirds of the nearly 2800 participants used biologics. Of the patients taking biologics, 16% had switched drugs at least once.

According to, “Forty-seven percent of those patients were prescribed omalizumab (Xolair), which targets immunoglobulin E (IgE). The next most used biologics were the interleukin 5 (IL-5) alpha receptor–targeting benralizumab (Fasenra; 27%) and mepolizumab (Nucala; 26%), which targets IL-5. Another 18% of patients were taking dupilumab (Dupixent), which targets the IL-4 alpha receptor. Three percent of patients were taking reslizumab (Cinqair), another therapy targeting IL-5. Nearly 9 in 10 patients (89%) who started taking biologics reported ongoing usage.”

To read more, click here.